Search Results

Dianthus Therapeutics, Inc. today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York.

Dianthus Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced its participation in the Bank of America Securities 2024 Health Care Conference.

Dianthus Therapeutics, Inc. announced U.S. Food and Drug Administration clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

Dianthus Therapeutics, Inc. announced that it granted equity awards on May 1, 2024, to two newly-hired, non-executive employees.

Dianthus Therapeutics, Inc. today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.

Dianthus Therapeutics, Inc. announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee.